Andrew C. Phillips
- Oncology top 1%
- Cancer-related Molecular Pathways 11
- HER2/EGFR in Cancer Research 6
- Biotechnology top 1%
- Cancer Research and Treatments 5
- Molecular Biology top 5%
- Ubiquitin and proteasome pathways 6
- Epigenetics and DNA Methylation 5
- RNA modifications and cancer 3
- Cell death mechanisms and regulation 3
- Cancer Research top 5%
- Cell Biology top 5%
-
- Monoclonal and Polyclonal Antibodies Research 6
Andrew C. Phillips
29 papers receiving 2.7k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Oncology 1.7k
- Biotechnology 333
- Molecular Biology 2.1k
- Cancer Research 378
- Cell Biology 270
Countries citing papers authored by Andrew C. Phillips
This map shows the geographic impact of Andrew C. Phillips's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew C. Phillips with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew C. Phillips more than expected).
Fields of papers citing papers by Andrew C. Phillips
This network shows the impact of papers produced by Andrew C. Phillips. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew C. Phillips. The network helps show where Andrew C. Phillips may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andrew C. Phillips, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2023 | 7 | |
| 3 | 2022 | 2 | |
| 4 | 2021 | 9 | |
| 5 | 2018 | 1 | |
| 6 | 2016 | 136 | |
| 7 | 2009 | 26 | |
| 8 | 2008 | 26 | |
| 9 | 2007 | 24 | |
| 10 | 2006 | 44 | |
| 11 | 2005 | 263 | |
| 12 | Regulation and function of the p53 tumor suppressor proteinbreakdown → | 2001 | 591 |
| 13 | 2001 | 114 | |
| 14 | Role for the p53 homologue p73 in E2F-1-induced apoptosisbreakdown → | 2000 | 592 |
| 15 | 2000 | 19 | |
| 16 | 1999 | 204 | |
| 17 | 1998 | 149 | |
| 18 | 1997 | 237 | |
| 19 | 1997 | 46 | |
| 20 | 1991 | 8 |
About Andrew C. Phillips
Andrew C. Phillips is a scholar working on Oncology, Biotechnology and Radiology, Nuclear Medicine and Imaging, having authored 29 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (11 papers), Ubiquitin and proteasome pathways (6 papers), HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Cancer Research and Treatments (5 papers), Epigenetics and DNA Methylation (5 papers), RNA modifications and cancer (3 papers) and Cell death mechanisms and regulation (3 papers). The work is most often cited by research in Oncology (1.7k citations), Biotechnology (333 citations) and Molecular Biology (2.1k citations). Andrew C. Phillips has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Karen H. Vousden, Kevin M. Ryan, Stewart Bates, Meredith S. Irwin, Elsa R. Flores, Jeremy C. Smith, Tyler Jacks, Wanguo Liu, Kenneth Y. Tsai and María C. Marín. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, Annals of Oncology, Journal of Clinical Oncology and Nucleic Acids Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.